SMC accepts entrectinib for adult and paediatric patients with solid tumours expressing an NTRK gene fusion

A pooled analysis of three phase I/II studies showed 64% of patients achieved an objective response with entrectinib treatment.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in